Torin 1

For research use only.

Catalog No.S2827

116 publications

CAS No. 1222998-36-8

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

Selleck's Torin 1 has been cited by 116 publications

Cell, 2020, 25;181(7):1596-1611.e27.

PubMed: 32559461 ( click the link to review the publication )

Nat Biotechnol, 2020, 38(5):638-648

PubMed: 32249828 ( click the link to review the publication )

Cell, 2019, 177(4):896-909

PubMed: 31030999 ( click the link to review the publication )

Nat Immunol, 2018, 19(12):1330-1340

PubMed: 30420624 ( click the link to review the publication )

Cell Metab, 2018, 28(3):369-382

PubMed: 30043754 ( click the link to review the publication )

Nature, 2017, 1;546(7656):168-172.

PubMed: 28538732 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Sci Transl Med, 2020, 12(548):eaay5691

PubMed: 32554707 ( click the link to review the publication )

Nat Commun, 2020, 24;11(1):479

PubMed: 31980602 ( click the link to review the publication )

Autophagy, 2020, 15:1-13

PubMed: 32264736 ( click the link to review the publication )

Cell Rep, 2020, 30(5):1400-1416

PubMed: 32023458 ( click the link to review the publication )

Cell Rep, 2020, 30(6):1835-1847

PubMed: 32049014 ( click the link to review the publication )

PLoS Pathog, 2020, 9;16(6):e1008568

PubMed: 32516328 ( click the link to review the publication )

Cell Death Dis, 2020, 8;5:e1214

PubMed: 24810050 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439931 ( click the link to review the publication )

Mol Nutr Food Res, 2020, 1;e1901231

PubMed: 32476238 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786

PubMed: 32169890 ( click the link to review the publication )

Int J Mol Sci, 2020, 24;21(6) pii: E2240

PubMed: 32213867 ( click the link to review the publication )

Exp Cell Res, 2020, 10.1016/j.yexcr.2020.111981

PubMed: 32234375 ( click the link to review the publication )

J Clin Invest, 2020, 137585

PubMed: 32673292 ( click the link to review the publication )

Emerg Microbes Infect, 2020, 9(1):1748-1760

PubMed: 32691695 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.13703

PubMed: 32683324 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:1364147

PubMed: 32724488 ( click the link to review the publication )

Nat Metab, 2020, 2(1):41-49

PubMed: 31993556 ( click the link to review the publication )
Cancer Res, 2020, 80(3):444-457

PubMed: 31722999 ( click the link to review the publication )

Mol Cell, 2019, 73(4):788-802

PubMed: 30704899 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4741

PubMed: 31628323 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1693

PubMed: 30979895 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5681

PubMed: 31831743 ( click the link to review the publication )

Autophagy, 2019, 15(3):493-509

PubMed: 30304977 ( click the link to review the publication )

Autophagy, 2019, 1-13

PubMed: 30957628 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1703353

PubMed: 31847700 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1628536

PubMed: 31203721 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 10.1073/pnas.1911393116

PubMed: 31732667 ( click the link to review the publication )

Cell Rep, 2019, 29(3):589-602

PubMed: 31618629 ( click the link to review the publication )

Cell Rep, 2019, 27(7):2075-2091.e5

PubMed: 31091447 ( click the link to review the publication )

Cell Mol Immunol, 2019, 10.1038/s41423-019-0281-6

PubMed: 31467416 ( click the link to review the publication )

Oncogene, 2019, 38(10):1639-1650

PubMed: 30337688 ( click the link to review the publication )

Oncogene, 2019, 10.1038/s41388-019-1085-y

PubMed: 31685947 ( click the link to review the publication )

Oncogene, 2019, 38(2):209-227

PubMed: 30087437 ( click the link to review the publication )

EBioMedicine, 2019, 40:151-162

PubMed: 30711516 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):399

PubMed: 31113939 ( click the link to review the publication )

Lab Invest, 2019, 99(5):648-658

PubMed: 30679758 ( click the link to review the publication )

Biochem Pharmacol, 2019, 162:191-201

PubMed: 30471247 ( click the link to review the publication )

J Biol Chem, 2019, 294(10):3760-3771

PubMed: 30617181 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 519(4):909-915

PubMed: 31563324 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4831

PubMed: 30446646 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5426

PubMed: 30575721 ( click the link to review the publication )
Nat Commun, 2018, 9(1):2819

PubMed: 30026551 ( click the link to review the publication )

J Pathol, 2018, 245(2):235-248

PubMed: 29570219 ( click the link to review the publication )

PLoS Genet, 2018, 14(5):e1007369

PubMed: 29750810 ( click the link to review the publication )

Development, 2018, 145(18)

PubMed: 30126904 ( click the link to review the publication )

Lung Cancer, 2018, 120:34-45

PubMed: 29748013 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Exp Cell Res, 2018, 363(1):84-94

PubMed: 29289595 ( click the link to review the publication )

Braz J Med Biol Res, 2018, 51(6):e7080

PubMed: 29694502 ( click the link to review the publication )

Cell Res, 2017, 27(2):184-201

PubMed: 27934868 ( click the link to review the publication )

Mol Cell, 2017, 67(6):907-921

PubMed: 28844862 ( click the link to review the publication )

Mol Cell, 2017, 65(6):1029-1043

PubMed: 28306502 ( click the link to review the publication )

Nat Commun, 2017, 8:15045

PubMed: 28429794 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Autophagy, 2017, 13(8):1364-1385

PubMed: 28598230 ( click the link to review the publication )

Autophagy, 2017, 13(4):686-702

PubMed: 28121484 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )

PLoS Pathog, 2017, 13(3):e1006249

PubMed: 28249048 ( click the link to review the publication )

Sci Rep, 2017, 7(1):13832

PubMed: 29062139 ( click the link to review the publication )

J Biol Chem, 2017, 292(35):14544-14555

PubMed: 28684424 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2017, 313(5):C501-C515

PubMed: 28794108 ( click the link to review the publication )

J Agric Food Chem, 2017, 65(31):6625-6637

PubMed: 28697598 ( click the link to review the publication )

Radiat Res, 2017, 187(3):382-396

PubMed: 28327001 ( click the link to review the publication )

Oncotarget, 2017, 8(65):109848-109856

PubMed: 29312653 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93688-93703

PubMed: 29212182 ( click the link to review the publication )
Oncotarget, 2017, 8(52):89527-89538

PubMed: 29163768 ( click the link to review the publication )

Oncotarget, 2017, 8(65):109848-109856

PubMed: 29312653 ( click the link to review the publication )

Oncotarget, 2017, 8(27):44550-44566

PubMed: 28562352 ( click the link to review the publication )

Protein Cell, 2016, 7(12):878-887

PubMed: 27909983 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3535-3551

PubMed: 28077803 ( click the link to review the publication )

Stem Cells Transl Med, 2016, 5(5):580-90

PubMed: 27025692 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(5):1428-37

PubMed: 26938669 ( click the link to review the publication )

Mol Biol Cell, 2016, 27(2):321-33

PubMed: 26582390 ( click the link to review the publication )

J Biol Chem, 2016, 291(33):17467-77

PubMed: 27339899 ( click the link to review the publication )

J Cell Physiol, 2016, 10.1002/jcp.25456

PubMed: 27301841 ( click the link to review the publication )

Front Plant Sci, 2016, 7:1746

PubMed: 27917191 ( click the link to review the publication )

BMC Musculoskelet Disord, 2016, 17:150

PubMed: 27052304 ( click the link to review the publication )

Oncotarget, 2016, 7(34):55690-55703

PubMed: 27494886 ( click the link to review the publication )

Oncotarget, 2016, 7(36):57525-57544

PubMed: 27438153 ( click the link to review the publication )

J Clin Invest, 2015, 125(3):1174-88

PubMed: 25664849 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25846574 ( click the link to review the publication )

J Med Chem, 2015, 58(16):6559-73

PubMed: 26237138 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:15

PubMed: 25849580 ( click the link to review the publication )

J Cell Physiol, 2015, 230(5):1064-74

PubMed: 25283437 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: 25582703 ( click the link to review the publication )

J Virol, 2015, 89(1):626-42

PubMed: 25339775 ( click the link to review the publication )

Sci Rep, 2015, 5:13891

PubMed: 26403635 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074/jbc.M114.621706

PubMed: 25878248 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )
J Biol Chem, 2015, 290(9):5592-605

PubMed: 25561726 ( click the link to review the publication )

Cell Signal, 2015, 27(8):1557-68

PubMed: 25936523 ( click the link to review the publication )

BMC Cancer, 2015, 15:855

PubMed: 26542945 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0135614

PubMed: 26267903 ( click the link to review the publication )

Oncotarget, 2015, 6(27):23238-48

PubMed: 26177051 ( click the link to review the publication )

PLoS Pathog, 2014, 10(6):e1004196

PubMed: 24945378 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1214

PubMed: 24810050 ( click the link to review the publication )

Am J Pathol, 2014, 184(1):214-29

PubMed: 24215913 ( click the link to review the publication )

J Biol Chem, 2014, 289(43):29739-49

PubMed: 25164809 ( click the link to review the publication )

J Biol Chem, 2014, 289(25):17830-42

PubMed: 24798333 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(24):4474-84

PubMed: 25288641 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.05.047

PubMed: 24858682 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12715-27

PubMed: 25587030 ( click the link to review the publication )

Oncotarget, 2014, 5(16):6816-31

PubMed: 25149175 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Blood, 2013, 121(18):3619-30

PubMed: 23444404 ( click the link to review the publication )

Trends Microbiol, 2013, 21(6):286-95

PubMed: 23608036 ( click the link to review the publication )

Genes Dev, 2013, 27(10):1115-31

PubMed: 23699409 ( click the link to review the publication )

PLoS One, 2013, 8(11):e80070

PubMed: 24244612 ( click the link to review the publication )

EMBO Mol Med, 2011, 3(4):189-200

PubMed: 21412983 ( click the link to review the publication )

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

Targets

mTORC1 ^[1] (Cell-free assay)	mTOR ^[2] (Cell-free assay)	DNA-PK ^[2] (Cell-free assay)	mTORC2 ^[1] (Cell-free assay)	p110γ ^[2] (Cell-free assay)	View More
2 nM	4.32 nM	6.34 nM	10 nM	171 nM	View More

In vitro

Torin1 inhibits phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 and 10 nM, respectively. Moreover, Torin1 exhibits 1000-fold selectivity for mTOR over PI3K (EC50 = 1800 nM) and exhibits 100-fold binding selectivity relative to 450 other protein kinases. ^[1] ^[2] Torin1 causes cell cycle arrest through a rapamycin-resistant mechanism that is also independent of mTORC2. Torin1 disrupts mTORC1-dependent phenotypes more completely than rapamycin. Rapamycin-resistant functions of mTORC1 are required for cap-dependent translation. ^[1] In a recent study, it is reported Torin1 increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
ETK-1	NUTNbGRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFz2U3VKSzVyPUCuNFAxOzB4IN88US=>	M2DIeHNCVkeHUh?=
OCUB-M	NX;aenRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXOTWM2OD1yLkCwNVk1KM7:TR?=	MXHTRW5ITVJ?
DOHH-2	NV7qVWJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7LSmNxUUN3ME2wMlAxOjJ3IN88US=>	NH7PPY1USU6JRWK=
NOS-1	NXrxWVlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTBwMECyOFIh\|ryP	M2r3UnNCVkeHUh?=
L-363	NXfldldWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHMdHlKUUN3ME2wMlAxOjh2IN88US=>	NFfT[XBUSU6JRWK=
RL95-2	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTBwMECzNkDPxE1?	M{n0eXNCVkeHUh?=
BL-70	M2D1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU[3fY1SUUN3ME2wMlAxOzN5IN88US=>	NIPCSm5USU6JRWK=
TGBC1TKB	NWrhR4pET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLzTWM2OD1yLkCwN\|c6KM7:TR?=	NFvKcnpUSU6JRWK=
697	MoTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7Gc4M1UUN3ME2wMlAxPjN2IN88US=>	M1\pWXNCVkeHUh?=
RPMI-8226	NELJO3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDyTYxKSzVyPUCuNFA3PTFizszN	MXvTRW5ITVJ?
BL-41	NFXP[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVX3b\|NOUUN3ME2wMlAxPjl4IN88US=>	M{TRcHNCVkeHUh?=
MRK-nu-1	M4jsPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjy[mJKSzVyPUCuNFA4ODdizszN	NF7wdoVUSU6JRWK=
EW-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4frSWlEPTB;MD6wNFc1QSEQvF2=	NUT1eWFlW0GQR1XS
EVSA-T	NYnabJVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXCRWdKSzVyPUCuNFA5QTJizszN	NGfvWlFUSU6JRWK=
HUTU-80	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTBwMEC5Nlkh\|ryP	MkTCV2FPT0WU
VA-ES-BJ	NX7odFVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2qzPWlEPTB;MD6wNFk5PCEQvF2=	MmLDV2FPT0WU
GCIY	NHnmd\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVi2UGRLUUN3ME2wMlAyODB5IN88US=>	NYixW3hHW0GQR1XS
ES6	NEHRb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTBwMEGwPFMh\|ryP	MkDYV2FPT0WU
NALM-6	NH[yZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PMUWlEPTB;MD6wNVExOiEQvF2=	NI\Q[GNUSU6JRWK=
LB996-RCC	MlzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXETWM2OD1yLkCxNVM4KM7:TR?=	NUDXUVVKW0GQR1XS
EW-16	NX;icnl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TlO2lEPTB;MD6wNVE6OiEQvF2=	NImwb4lUSU6JRWK=
KALS-1	NV3Ed2FLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7JZ\|E6UUN3ME2wMlAyOTl6IN88US=>	MkTEV2FPT0WU
OPM-2	NFrtR3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnOUmtSUUN3ME2wMlAyOjlizszN	NHWyVmdUSU6JRWK=
KU812	NYrDcZNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTBwMEGyPVYh\|ryP	NV\lZZhqW0GQR1XS
A4-Fuk	NXj6VnZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofrTWM2OD1yLkCxN\|E6KM7:TR?=	MkTJV2FPT0WU
KGN	M{jreGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nVOWlEPTB;MD6wNVM2QSEQvF2=	NWjYd\|F2W0GQR1XS
KS-1	NHX5PYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDsUlNYUUN3ME2wMlAyOzl{IN88US=>	MkLuV2FPT0WU
no-11	NG\sNYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;ETWM2OD1yLkCxN\|k2KM7:TR?=	NWHOTmdnW0GQR1XS
PSN1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnS[5g3UUN3ME2wMlAyPDB7IN88US=>	MmjEV2FPT0WU
SK-LMS-1	NGTKOVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTBwMEG0NVMh\|ryP	NVfFZpRtW0GQR1XS
LS-411N	M3PaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2ftcGlEPTB;MD6wNVQ{QSEQvF2=	NVLoOZFEW0GQR1XS
HT-144	MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPlcFJLUUN3ME2wMlAyPDVzIN88US=>	M4DlWHNCVkeHUh?=
ACN	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlj2TWM2OD1yLkCxOUDPxE1?	MWLTRW5ITVJ?
RKO	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVSzdIp[UUN3ME2wMlAyPTN\|IN88US=>	NEnoPIFUSU6JRWK=
CMK	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTMSmQ5UUN3ME2wMlAyPTR\|IN88US=>	MWnTRW5ITVJ?
GB-1	NGjZe5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4izb2lEPTB;MD6wNVU2OyEQvF2=	MmXLV2FPT0WU
KE-37	NWe5T5FZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XaUWlEPTB;MD6wNVU4OyEQvF2=	M3GzWnNCVkeHUh?=
no-10	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\kcWlEPTB;MD6wNVU5PCEQvF2=	MnPJV2FPT0WU
MOLT-16	MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTBwMEG2NlIh\|ryP	NVTjNohlW0GQR1XS
HEL	NVOxcFR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2raXmlEPTB;MD6wNVY1KM7:TR?=	M3Wxc3NCVkeHUh?=
NCI-H1355	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLRTWM2OD1yLkCxOlQ3KM7:TR?=	NHLLeFdUSU6JRWK=
IST-MEL1	MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljITWM2OD1yLkCxO\|c1KM7:TR?=	M4XlfHNCVkeHUh?=
MHH-PREB-1	M4DOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwMEG4NVgh\|ryP	MkTZV2FPT0WU
ES8	NX;vTYZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDqTWM2OD1yLkCxPFQ1KM7:TR?=	NV;wXnZWW0GQR1XS
LC-2-ad	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LifWlEPTB;MD6wNlE{PyEQvF2=	MnXiV2FPT0WU
LAMA-84	M3PLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;oXVVKSzVyPUCuNFIyPjdizszN	M2fLO3NCVkeHUh?=
BV-173	MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIO2ZWpKSzVyPUCuNFIzODNizszN	NGniZVBUSU6JRWK=
SW872	NEnBeIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXx[3hKSzVyPUCuNFIzPDdizszN	MkjaV2FPT0WU
SK-UT-1	Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\LemZKSzVyPUCuNFIzPjFizszN	MnzmV2FPT0WU
OS-RC-2	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTBwMEKzNlMh\|ryP	NEDNVplUSU6JRWK=
NCI-H747	M4jwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PnNWlEPTB;MD6wNlM{KM7:TR?=	MXnTRW5ITVJ?
MZ2-MEL	MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;1SWlEPTB;MD6wNlM{PyEQvF2=	MYHTRW5ITVJ?
TE-11	MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjRTWM2OD1yLkCyN\|czKM7:TR?=	NH7LSFdUSU6JRWK=
KURAMOCHI	NYHFdVZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTBwMEK0NVQh\|ryP	NVHxV\|B4W0GQR1XS
HD-MY-Z	NFjsdlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\KPWlEPTB;MD6wNlQzPiEQvF2=	MnHkV2FPT0WU
GI-1	NHnxXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\FSWlEPTB;MD6wNlQ3QSEQvF2=	MlezV2FPT0WU
LB1047-RCC	MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHX3UotKSzVyPUCuNFI1QDhizszN	MX7TRW5ITVJ?
TE-12	MoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\pSHBKSzVyPUCuNFI2PSEQvF2=	Mn\JV2FPT0WU
MZ7-mel	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHmxepZKSzVyPUCuNFI3ODlizszN	NV\6[FRnW0GQR1XS
MMAC-SF	NWqxNGRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTBwMEK2N\|Mh\|ryP	M4DXWnNCVkeHUh?=
A101D	M4i2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTBwMEK2OUDPxE1?	NI\tN\|hUSU6JRWK=
GR-ST	MkWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\0TWM2OD1yLkCyOlU2KM7:TR?=	M4fiS3NCVkeHUh?=
MC116	Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTBwMEK2PEDPxE1?	NFjYeJBUSU6JRWK=
Ramos-2G6-4C10	MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nBOGlEPTB;MD6wNlc2KM7:TR?=	MnvHV2FPT0WU
ATN-1	M1niSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLId3JPUUN3ME2wMlAzPzh7IN88US=>	NGDmRVNUSU6JRWK=
MFH-ino	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PncWlEPTB;MD6wNlgyOiEQvF2=	NHn4[YNUSU6JRWK=
DEL	NVHMfpBoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHKUZFKSzVyPUCuNFI5OTVizszN	M{Xt[3NCVkeHUh?=
OCI-AML2	MnLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonjTWM2OD1yLkCyPFcyKM7:TR?=	NF6zVGNUSU6JRWK=
LXF-289	Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\uV2lEPTB;MD6wNlg4OiEQvF2=	M33oU3NCVkeHUh?=
IA-LM	MmDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfmdnRKSzVyPUCuNFI6OTdizszN	MVXTRW5ITVJ?
EoL-1-cell	NGjDbXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfXWY9yUUN3ME2wMlAzQTl4IN88US=>	NEPCTI1USU6JRWK=
OVCAR-4	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTyZmxKSzVyPUCuNFMxQTRizszN	NFfXbZlUSU6JRWK=
ES1	MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTBwMEOwPVch\|ryP	NGD3N5VUSU6JRWK=
CESS	NWDHeZdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnT1TWM2OD1yLkCzNFk6KM7:TR?=	NHz2VmZUSU6JRWK=
GAK	NEHoe3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zsdGlEPTB;MD6wN\|E5PiEQvF2=	NGCxR4dUSU6JRWK=
NTERA-S-cl-D1	Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPo[5VKSzVyPUCuNFMzOjZizszN	NFHvXFFUSU6JRWK=
TE-10	NF\rV5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFyyZXdKSzVyPUCuNFM{OTFizszN	Ml;YV2FPT0WU
CCRF-CEM	NULXeHVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWK2WJZIUUN3ME2wMlA{OzdzIN88US=>	MUPTRW5ITVJ?
NMC-G1	NHX0TnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTBwMEO0OFgh\|ryP	MUfTRW5ITVJ?
HOP-62	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\me4hKSzVyPUCuNFM2PTZizszN	NXXm[JV2W0GQR1XS
SH-4	MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTBwMEO1PFIh\|ryP	MorPV2FPT0WU
NCI-H1648	Mof2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDjOZpKSzVyPUCuNFM3OjJizszN	MVjTRW5ITVJ?
EB-3	M{X6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoD4TWM2OD1yLkCzOlQ{KM7:TR?=	M1rDVHNCVkeHUh?=
BB65-RCC	MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rSZWlEPTB;MD6wN\|Y6OSEQvF2=	NHnKbW9USU6JRWK=
BE-13	Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWraW2JxUUN3ME2wMlA{PzV7IN88US=>	MULTRW5ITVJ?
CP67-MEL	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\QOWlEPTB;MD6wN\|c2QSEQvF2=	MoDiV2FPT0WU
SW954	M{TjUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7TT5VIUUN3ME2wMlA{PzlizszN	M4jDZXNCVkeHUh?=
TE-5	NGjsVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoC2TWM2OD1yLkCzPFU1KM7:TR?=	MmG2V2FPT0WU
HCE-4	M330O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;xbWNKSzVyPUCuNFM5PTVizszN	NWXFVm9zW0GQR1XS
LC-1F	NV\MTXFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DuPWlEPTB;MD6wN\|k5QSEQvF2=	NWfXeoJWW0GQR1XS
TK10	M4fjfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGi1VGdKSzVyPUCuNFQxOTlizszN	MWjTRW5ITVJ?
SJSA-1	M2fuOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXNToVKSzVyPUCuNFQyQDhizszN	M1Sw[3NCVkeHUh?=
Daudi	NGnhT41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LkPGlEPTB;MD6wOFIzPSEQvF2=	NInSW4FUSU6JRWK=
SW982	M1TCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnOO3JKSzVyPUCuNFQzPDZizszN	M3nHSHNCVkeHUh?=
SF126	M2XwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwMESzOlEh\|ryP	MonZV2FPT0WU
TE-15	M2PiSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;U[4JkUUN3ME2wMlA1PDN3IN88US=>	MUDTRW5ITVJ?
COLO-684	NYrjXmtZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWX2N\|FXUUN3ME2wMlA1PTZzIN88US=>	MWjTRW5ITVJ?
8-MG-BA	NFPlfYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLNPW9KSzVyPUCuNFQ3OjlizszN	MWHTRW5ITVJ?
NB13	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlK0TWM2OD1yLkC0O\|c3KM7:TR?=	NVn4W3N3W0GQR1XS
HCC1599	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXzTWM2OD1yLkC0PFc6KM7:TR?=	NUfaOWVPW0GQR1XS
SK-PN-DW	NUDMe5JQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFSzUFJKSzVyPUCuNFQ6PDlizszN	M1jaV3NCVkeHUh?=
ALL-PO	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3radmlEPTB;MD6wOFk2PiEQvF2=	NVLuW2twW0GQR1XS
NB6	MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\ITWM2OD1yLkC1NlcyKM7:TR?=	NFztcY9USU6JRWK=
IST-SL2	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHFTWM2OD1yLkC1N\|YzKM7:TR?=	NVr3Upl[W0GQR1XS
BB30-HNC	NVzDbJVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjSTYhPUUN3ME2wMlA2PzNizszN	MoLmV2FPT0WU
SW962	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTBwMEW3OlMh\|ryP	M13QTnNCVkeHUh?=
TGBC24TKB	NVTSWVBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HWXWlEPTB;MD6wOVc6QSEQvF2=	Mn3jV2FPT0WU
KINGS-1	M4XVU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrNc5VnUUN3ME2wMlA2QDB\|IN88US=>	NV\hd2hPW0GQR1XS
HC-1	M4W2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDoXW5KSzVyPUCuNFU5OjdizszN	NISwc2xUSU6JRWK=
RS4-11	NYHkc\|B5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTBwMEW5N\|gh\|ryP	MmOyV2FPT0WU
LS-123	M4TSb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTBwMEW5OFIh\|ryP	MkD1V2FPT0WU
A3-KAW	NXH3cZdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHSUW5KSzVyPUCuNFYzOjVizszN	M4CydnNCVkeHUh?=
SNB75	NEfEWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPFTWM2OD1yLkC2N\|QyKM7:TR?=	M1TyVXNCVkeHUh?=
SR	NEO2OJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvpSmRNUUN3ME2wMlA3Ozd2IN88US=>	NIH0THZUSU6JRWK=
LOUCY	NFT3OVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zGPGlEPTB;MD6wOlM6PCEQvF2=	MWXTRW5ITVJ?
K5	MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETZTFVKSzVyPUCuNFY1ODNizszN	MV3TRW5ITVJ?
Becker	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnSTIpKSzVyPUCuNFY1OiEQvF2=	NGHzcohUSU6JRWK=
CTV-1	NFX5PVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\0TWM2OD1yLkC2OVQ5KM7:TR?=	NEjP[5hUSU6JRWK=
KLE	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LNcWlEPTB;MD6wOlU5PCEQvF2=	NWXqcmN3W0GQR1XS
MZ1-PC	NVy2So1lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HDZWlEPTB;MD6wOlU6QCEQvF2=	M3rQXXNCVkeHUh?=
MOLT-4	NHfaWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH71cZZKSzVyPUCuNFY3ODVizszN	MYfTRW5ITVJ?
MLMA	NGPvNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmKzTWM2OD1yLkC2O\|gh\|ryP	NIDWdodUSU6JRWK=
A388	M1rqdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zY[2lEPTB;MD6wOlg6OyEQvF2=	NUfPfmpJW0GQR1XS
MV-4-11	MkTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTBwME[5PVUh\|ryP	NX7z[ZlQW0GQR1XS
DSH1	NWLNZYhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTBwMEexO\|Mh\|ryP	NWj0UmlqW0GQR1XS
MONO-MAC-6	NFfkXpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PkOWlEPTB;MD6wO\|IyOiEQvF2=	M2\kVnNCVkeHUh?=
ARH-77	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzlTWM2OD1yLkC3Nlc5KM7:TR?=	M3vTR3NCVkeHUh?=
LB771-HNC	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwMEe1OFkh\|ryP	M{LiSHNCVkeHUh?=
PF-382	MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlz3TWM2OD1yLkC3OVY6KM7:TR?=	NYPZW\|JWW0GQR1XS
KM12	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rQPGlEPTB;MD6wO\|Y1KM7:TR?=	NVXLeXo5W0GQR1XS
HAL-01	NXnlfpZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDrdpZJUUN3ME2wMlA4PjV6IN88US=>	NXvMVpdJW0GQR1XS
RPMI-8402	Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXr5e3QxUUN3ME2wMlA4Pzh7IN88US=>	NH;0V2RUSU6JRWK=
OMC-1	M1zoN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXW0SnFNUUN3ME2wMlA4QDB2IN88US=>	MXzTRW5ITVJ?
HT	M{foTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TsS2lEPTB;MD6wPEDPxE1?	MmTmV2FPT0WU
QIMR-WIL	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzUUWdNUUN3ME2wMlA5ODV3IN88US=>	MUDTRW5ITVJ?
KNS-42	NGPyS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7WTWM2OD1yLkC4NlA{KM7:TR?=	MXTTRW5ITVJ?
BC-3	NUjyXGdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTCTWM2OD1yLkC4NlA1KM7:TR?=	NWnNZ4F5W0GQR1XS
ES4	M1K3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwMEiyPVYh\|ryP	Ml:5V2FPT0WU
NCI-H23	NUTuTXA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfRU2pCUUN3ME2wMlA5PDRizszN	M3vXNHNCVkeHUh?=
LB2518-MEL	NH\3cpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjRPWlKSzVyPUCuNFg3QTZizszN	M2TafnNCVkeHUh?=
LC4-1	Mnq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwMEi3N\|gh\|ryP	Mni0V2FPT0WU
SIG-M5	M3vNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoL4TWM2OD1yLkC4PVA1KM7:TR?=	M4jzR3NCVkeHUh?=
LP-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzSVWdKSzVyPUCuNFg6OzhizszN	NYDmWZdzW0GQR1XS
TE-8	M3LYZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rDcGlEPTB;MD6wPVAyPiEQvF2=	NXnEWGN5W0GQR1XS
K-562	Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMEmxNkDPxE1?	NWXxfWM2W0GQR1XS
J-RT3-T3-5	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXibWd3UUN3ME2wMlA6OTV\|IN88US=>	MXLTRW5ITVJ?
DU-4475	M2[3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTBwMEmxOlUh\|ryP	MorCV2FPT0WU
RXF393	NGDsemFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fNbGlEPTB;MD6wPVQ3OiEQvF2=	NYfVSXl5W0GQR1XS
NB5	M3r6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTMTWM2OD1yLkC5OlI2KM7:TR?=	M3fCUHNCVkeHUh?=
A704	M{\VeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MomwTWM2OD1yLkC5O\|QyKM7:TR?=	M1PHbnNCVkeHUh?=
SF268	MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\0VolmUUN3ME2wMlA6QDJ3IN88US=>	NXfnRXNMW0GQR1XS
UACC-257	M{jSUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DKcGlEPTB;MD6wPVg{OyEQvF2=	Mlr2V2FPT0WU
L-428	NGPIZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XwPGlEPTB;MD6xNFMzKM7:TR?=	NVnRcVA3W0GQR1XS
ST486	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTBwMUC2NFYh\|ryP	NEL2XldUSU6JRWK=
SK-MM-2	MoTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwMUC3NFkh\|ryP	MkfkV2FPT0WU
COR-L279	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjEdFJtUUN3ME2wMlExQDN{IN88US=>	NFu4VFJUSU6JRWK=
JiyoyeP-2003	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;OSWlEPTB;MD6xNFg1OyEQvF2=	NXjGXZlJW0GQR1XS
GT3TKB	MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwMUC5NVgh\|ryP	NFL3OnNUSU6JRWK=
HCE-T	NUm4dVlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTBwMUC5OEDPxE1?	MYnTRW5ITVJ?
SBC-1	NE\XOWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXoTWM2OD1yLkGxNVE6KM7:TR?=	M1;ScXNCVkeHUh?=
KNS-81-FD	NXHIZlk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LrZmlEPTB;MD6xNVI4OyEQvF2=	MVfTRW5ITVJ?
NCI-H2126	Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGS1XFZKSzVyPUCuNVE{QTRizszN	NI\iU3BUSU6JRWK=
EM-2	M4LGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\XTWM2OD1yLkGxOVI6KM7:TR?=	NWnUcXRiW0GQR1XS
JAR	NWLzW4RGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3VTWM2OD1yLkGxOVk5KM7:TR?=	MV\TRW5ITVJ?
NB17	NWXxUZZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTBwMUG2OVIh\|ryP	NV3KV2hJW0GQR1XS
LB647-SCLC	M{jBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTBwMUG3NFUh\|ryP	NGX5W3FUSU6JRWK=
CAL-148	MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzEdZJKSzVyPUCuNVE5KM7:TR?=	NH;IU3hUSU6JRWK=
K052	NUG0SYtmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1P4[WlEPTB;MD6xNVg2OSEQvF2=	M4TYTHNCVkeHUh?=
KARPAS-299	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEOxZXZKSzVyPUCuNVIzOzNizszN	M17WVnNCVkeHUh?=
KARPAS-422	M1raWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\JSnlpUUN3ME2wMlEzPDN{IN88US=>	NV;zWnhzW0GQR1XS
LOXIMVI	NWH4VG5lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HUdWlEPTB;MD6xNlUyPSEQvF2=	Mn\TV2FPT0WU
SCC-3	M2TueWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLDRpFKSzVyPUCuNVI5PTFizszN	M4LySXNCVkeHUh?=
LU-139	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HQZ2lEPTB;MD6xNlk4PSEQvF2=	MmLUV2FPT0WU
COLO-320-HSR	MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTBwMUOwPFYh\|ryP	NXztZZVMW0GQR1XS
ONS-76	M2e4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\QZVJKSzVyPUCuNVMyOyEQvF2=	NVLSOHB5W0GQR1XS
U-266	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnW1TWM2OD1yLkGzNlQ2KM7:TR?=	M3XmUXNCVkeHUh?=
HH	Mk\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTM[4UzUUN3ME2wMlE{PTN3IN88US=>	NX\ad2E3W0GQR1XS
BB49-HNC	NIPKWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2CwTmlEPTB;MD6xN\|U5PyEQvF2=	M1m5ZXNCVkeHUh?=
NCI-SNU-5	NIi1SlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjmWYtKSzVyPUCuNVM2QTZizszN	MWjTRW5ITVJ?
C2BBe1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLRTWM2OD1yLkGzO\|Q3KM7:TR?=	NVy3UGlsW0GQR1XS
ML-2	MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHG1dVZKSzVyPUCuNVM6PTNizszN	M3zkPHNCVkeHUh?=
SCH	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHzTWM2OD1yLkGzPVc1KM7:TR?=	MVXTRW5ITVJ?
NCI-H82	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTBwMUSxNFQh\|ryP	M4G1SnNCVkeHUh?=
MDA-MB-134-VI	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHlcVBKSzVyPUCuNVQzPTJizszN	NUKzXpZmW0GQR1XS
SK-N-DZ	MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvGTWM2OD1yLkG0O\|E6KM7:TR?=	NYrJeIJkW0GQR1XS
HL-60	NFTUfIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHvXXhPUUN3ME2wMlE1QTJizszN	NHXvblFUSU6JRWK=
LB373-MEL-D	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\wPJFKSzVyPUCuNVU2OzlizszN	NUf6U5ZkW0GQR1XS
LB831-BLC	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LF[WlEPTB;MD6xOlA4PiEQvF2=	M3zmZXNCVkeHUh?=
SK-NEP-1	M3XQ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\RVHloUUN3ME2wMlE3OTBzIN88US=>	MnjHV2FPT0WU
IMR-5	NI[1cWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwMU[0PFMh\|ryP	MknSV2FPT0WU
Calu-6	M2TLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGe4S4dKSzVyPUCuNVY2OzdizszN	NVjYZ4d3W0GQR1XS
NCI-H1882	M3S1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPuVVBWUUN3ME2wMlE3PzJ6IN88US=>	NEnYeZRUSU6JRWK=
NCI-H446	M1XlZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rGeWlEPTB;MD6xOlg6OSEQvF2=	M4HkXnNCVkeHUh?=
GI-ME-N	MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYOySndRUUN3ME2wMlE5ODJizszN	NHHvRZNUSU6JRWK=
MPP-89	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTBwMUixNlEh\|ryP	NV;pfo1FW0GQR1XS
CGTH-W-1	NGjSfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\sTWM2OD1yLkG4OFM3KM7:TR?=	MmnlV2FPT0WU
MEG-01	NF\j[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTBwMUi2Nlgh\|ryP	NILr[GRUSU6JRWK=
NCI-H748	M{PhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojCTWM2OD1yLkG4PVEyKM7:TR?=	NVvJSld4W0GQR1XS
COLO-829	MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwMkC2O\|Mh\|ryP	NWrqTlVIW0GQR1XS
GOTO	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17CT2lEPTB;MD6yNFc{KM7:TR?=	M4TubnNCVkeHUh?=
EW-3	NHnoRZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fnUmlEPTB;MD6yNVcyQCEQvF2=	NIHtOI9USU6JRWK=
KY821	M{HofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvRTWM2OD1yLkKyNFQ2KM7:TR?=	M3vSPHNCVkeHUh?=
CTB-1	MnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHNTWM2OD1yLkKyNlI5KM7:TR?=	NX65UFQ4W0GQR1XS
TALL-1	M4LYZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DL[GlEPTB;MD6yNlkzOSEQvF2=	NEL6SmNUSU6JRWK=
NCI-H209	NHL4WYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXIcXY6UUN3ME2wMlIzQTZ{IN88US=>	NGPSOWVUSU6JRWK=
IST-MES1	NX\Qc4g6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPkeYRKSzVyPUCuNlM2OSEQvF2=	NWT6XW9tW0GQR1XS
DMS-114	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLDV5lKSzVyPUCuNlM6QTNizszN	M1;pVXNCVkeHUh?=
SNU-C2B	MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLNTWM2OD1yLkK0N\|E3KM7:TR?=	NEjwbJFUSU6JRWK=
DG-75	M3L0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTBwMk[xPVUh\|ryP	NWTK[2ZXW0GQR1XS
D-336MG	NVz2OHhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;tVWZKSzVyPUCuNlY2PTdizszN	Ml[1V2FPT0WU
KMOE-2	M2DQcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTwfZZKSzVyPUCuNlc2OzhizszN	M1zvOHNCVkeHUh?=
NB1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XSbWlEPTB;MD6yO\|kzPiEQvF2=	M2PBZXNCVkeHUh?=
RH-1	Ml7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PFb2lEPTB;MD6yO\|k5QSEQvF2=	MX7TRW5ITVJ?
TE-1	NELnc49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3f0fmlEPTB;MD6yPFQ4QSEQvF2=	M{nhRnNCVkeHUh?=
RPMI-6666	NGDQVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGD4NodKSzVyPUCuNlg5PCEQvF2=	M2S3eHNCVkeHUh?=
TE-9	NWHpOYJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTBwMki5PFUh\|ryP	MYDTRW5ITVJ?
BT-474	MkG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFO1eZlKSzVyPUCuNlk{OzRizszN	M13tOXNCVkeHUh?=
COLO-668	MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;peJlKSzVyPUCuNlk1OjlizszN	NFnZW4pUSU6JRWK=
NCI-H1581	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkK2TWM2OD1yLkK5Olg6KM7:TR?=	NHjSbmpUSU6JRWK=
MN-60	NFjGZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;hTWM2OD1yLkK5PVA2KM7:TR?=	M1;te3NCVkeHUh?=
L-540	NXexSIRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTBwM{CwPFEh\|ryP	NGnBcodUSU6JRWK=
MOLT-13	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DZO2lEPTB;MD6zNFE5OyEQvF2=	NFzvPW5USU6JRWK=
NCI-SNU-16	MmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXVe5VUUUN3ME2wMlMxOjB3IN88US=>	MoHhV2FPT0WU
NCI-H64	MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTBwM{CzN\|Eh\|ryP	NXPLZVRbW0GQR1XS
CP66-MEL	MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPqTXdsUUN3ME2wMlMyPDF3IN88US=>	NGjqU2ZUSU6JRWK=
NB69	M4DONmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HrOWlEPTB;MD6zNlE5QCEQvF2=	NXvIdpZSW0GQR1XS
NCI-H2196	M1zFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFj0RZNKSzVyPUCuN\|MxOzZizszN	NUfaXpNMW0GQR1XS
MHH-CALL-2	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M375eGlEPTB;MD6zN\|Q3QCEQvF2=	MWrTRW5ITVJ?
HCC2157	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXu1[5BlUUN3ME2wMlM{QTV2IN88US=>	MnnWV2FPT0WU
LS-1034	MmXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjUcHllUUN3ME2wMlM3Ozh6IN88US=>	MlGzV2FPT0WU
BOKU	MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HxNWlEPTB;MD6zO\|E6QSEQvF2=	M2\UO3NCVkeHUh?=
GDM-1	NXXmOo01T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnRVYVKSzVyPUCuN\|czOzRizszN	M1nPc3NCVkeHUh?=
TGW	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTBwM{e0OVMh\|ryP	M2j6bHNCVkeHUh?=
SNU-C1	M4HIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLaTWM2OD1yLkO4NlE2KM7:TR?=	NYrsT\|VPW0GQR1XS
LS-513	NWTnSY53T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{i0VGlEPTB;MD6zPVA4OSEQvF2=	NV7pU3diW0GQR1XS
NOMO-1	NWHXe3d{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnad4dVUUN3ME2wMlM6QTdzIN88US=>	MlfjV2FPT0WU
MS-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULpO4dSUUN3ME2wMlQxOTd5IN88US=>	MVTTRW5ITVJ?
EKVX	M1vsS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPvN444UUN3ME2wMlQ1PDZzIN88US=>	MlH4V2FPT0WU
SK-MEL-2	NU\0UHFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHheGxzUUN3ME2wMlQ3PCEQvF2=	NX\FRZZzW0GQR1XS
HCC1187	M1vzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH65UXVKSzVyPUCuOFY4PjhizszN	MnLXV2FPT0WU
HCC2218	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETJZ\|JKSzVyPUCuOFczOjdizszN	M2T4XXNCVkeHUh?=
NCI-H187	NIDo[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTBwNEe4OEDPxE1?	NXrRfWZzW0GQR1XS
DB	NGK2OHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTBwNUCwOVUh\|ryP	MUPTRW5ITVJ?
NCI-H69	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PSOGlEPTB;MD61NFI1PyEQvF2=	MYXTRW5ITVJ?
NCI-H1694	MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPRUJZKSzVyPUCuOVA3QTdizszN	NFvFPHZUSU6JRWK=
CA46	NYfiRmdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDoTWM2OD1yLkWwPVE4KM7:TR?=	M4Szc3NCVkeHUh?=
EHEB	Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfXfIhKSzVyPUCuOVEyQTNizszN	M2PSNXNCVkeHUh?=
NCCIT	NHTQZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PEdGlEPTB;MD61OFMzOSEQvF2=	M2\yfnNCVkeHUh?=
NCI-H720	NGrBcnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nOTGlEPTB;MD61OFk3OiEQvF2=	M2PKUnNCVkeHUh?=
LU-134-A	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTmTWM2OD1yLkW1Nlk3KM7:TR?=	M2jiOnNCVkeHUh?=
MC-CAR	NF32c\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{f3OGlEPTB;MD61OVQ{OSEQvF2=	MVPTRW5ITVJ?
NEC8	Ml\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fsW2lEPTB;MD61OlE4OiEQvF2=	M2TDS3NCVkeHUh?=
NCI-H524	M4W4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwNUi3OFgh\|ryP	NWHaNpk1W0GQR1XS
NCI-H1963	NV7rWmlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTBwNkK1PEDPxE1?	MmrCV2FPT0WU
SU-DHL-1	NV3yVWZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NID3UYRKSzVyPUCuOlQ2OjZizszN	MXPTRW5ITVJ?
NCI-H1522	M1zvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\JV5pLUUN3ME2wMlY1QDh\|IN88US=>	NHjTVWdUSU6JRWK=
NCI-H1155	NF;Jc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;OdnlKSzVyPUCuOlU{PSEQvF2=	MUjTRW5ITVJ?
D-263MG	M1rzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\jZWlEPTB;MD62OlExOSEQvF2=	MWnTRW5ITVJ?
TE-6	NUfuXZhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\WTWM2OD1yLk[4NVA1KM7:TR?=	Ml[xV2FPT0WU
NCI-H1417	NWLGdJE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;qbGpKUUN3ME2wMlY6PzFzIN88US=>	Mnu4V2FPT0WU
NCI-H510A	NVe0XIRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\tZmlEPTB;MD63O\|I{PiEQvF2=	MWLTRW5ITVJ?
KARPAS-45	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwN{iyN\|Uh\|ryP	MWPTRW5ITVJ?
IST-SL1	NUW2c3lUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nkSWlEPTB;MD64OVgzPSEQvF2=	NEizSXpUSU6JRWK=
COLO-824	NXvn[pp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LPZWlEPTB;MD64O\|g{PSEQvF2=	M{npOHNCVkeHUh?=
NCI-H526	MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7zfItKSzVyPUCuPVA6PThizszN	MW\TRW5ITVJ?
NCI-H719	M4TjWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnrTWM2OD1yLkm2OlU4KM7:TR?=	MnjzV2FPT0WU
SF539	NEnpVpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTBwOUizPVYh\|ryP	NHXYW\|RUSU6JRWK=
NKM-1	M33qZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwOUi2OlMh\|ryP	MkTNV2FPT0WU
A253	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4X1NmlEPTB;MD65PFg5PSEQvF2=	NYHTUYp[W0GQR1XS
TE-441-T	NUDscYdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3Pe3pKSzVyPUGuNFQ{PSEQvF2=	NWHpemtWW0GQR1XS
COR-L88	NIizdmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPHZXA6UUN3ME2xMlEyOzV2IN88US=>	MXrTRW5ITVJ?
CPC-N	M2PUZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzLUpJUUUN3ME2xMlE2QDh6IN88US=>	NEjIbJNUSU6JRWK=
NCI-H2107	MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2K1VWlEPTB;MT6xO\|I3OSEQvF2=	NHfl[\|JUSU6JRWK=
ECC4	MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonUTWM2OD1zLkG4Olk{KM7:TR?=	NX;OXYlVW0GQR1XS
NCI-H2141	NV;DVGxjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTFwMUmyPVkh\|ryP	M2r4PHNCVkeHUh?=
NCI-H1770	NES4R41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HnXmlEPTB;MT6zNlkzQCEQvF2=	NEP6RmdUSU6JRWK=
NCI-SNU-1	M3;TfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDnTWM2OD1zLkOzNFQh\|ryP	NGX5cm5USU6JRWK=
LU-165	M{TwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nhcGlEPTB;MT60OVQ3PyEQvF2=	MUXTRW5ITVJ?
Raji	NUTJTlRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33kSmlEPTB;MT60O\|I2QSEQvF2=	MlfTV2FPT0WU
EW-24	NUD6W294T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTFwNUS2NVkh\|ryP	MUDTRW5ITVJ?
KP-N-RT-BM-1	NGnpNItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LNSWlEPTB;MT61OlU2OSEQvF2=	MmD1V2FPT0WU
SK-MEL-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{S5RmlEPTB;MT62OFg4PyEQvF2=	NYfpbpBlW0GQR1XS
SCLC-21H	NYnUO\|R3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXWOJQ5UUN3ME2xMlY3PjVzIN88US=>	MoTmV2FPT0WU
SIMA	M2fhfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEO1WYNKSzVyPUGuOlgzOzNizszN	M2\JSHNCVkeHUh?=
NCI-H1304	M{PUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXxTWM2OD1zLkewO\|Y2KM7:TR?=	MlG2V2FPT0WU
REH	Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXpRmI{UUN3ME2xMlcyODd6IN88US=>	MWnTRW5ITVJ?
KP-N-YS	NGrP[WtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoT4TWM2OD1zLkmzOVUyKM7:TR?=	MYDTRW5ITVJ?
DMS-153	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3u3dWlEPTB;MT65O\|U6KM7:TR?=	Mk\0V2FPT0WU
NB10	NX6yNoxpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;GZ2lEPTB;Mj6yNFg4QCEQvF2=	M1TqWHNCVkeHUh?=
NCI-H345	M2\0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHuxOHRKSzVyPUKuOlE6ODVizszN	M2\DcXNCVkeHUh?=
SK-N-FI	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXqcpFKSzVyPUKuO\|U{QDFizszN	NGfIfXZUSU6JRWK=
NCI-H1092	NXmz[GJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTJwOUWzPVQh\|ryP	M{Oyb3NCVkeHUh?=
KM-H2	NXjwT\|lLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFn6fohKSzVyPUOuOlU{QTZizszN	NVOzR3B7W0GQR1XS
KG-1	NVjMeYVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXVXXVrUUN3ME2zMlcyPjh6IN88US=>	M2HORXNCVkeHUh?=
D-283MED	NY[ybG9ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXGUFNtUUN3ME2zMlc2QDdizszN	MVvTRW5ITVJ?
LU-65	NGHaT21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3P5R2lEPTB;ND6xNVQ5PSEQvF2=	M3zKVHNCVkeHUh?=
MSTO-211H	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljlTWM2OD12LkG4PFk5KM7:TR?=	Mn3TV2FPT0WU
NCI-H2081	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlSwTWM2OD12LkK5NVc1KM7:TR?=	NEW4VXpUSU6JRWK=
D-247MG	NV3ZT4pTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1m1bWlEPTB;ND60N\|E6OSEQvF2=	Ml20V2FPT0WU
P31-FUJ	NHjnUFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInyUJdKSzVyPUSuOFUxOTlizszN	NYPYU211W0GQR1XS
DMS-79	NHzjTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzzTWM2OD12LkmzNVg{KM7:TR?=	NGrTZZRUSU6JRWK=
KASUMI-1	MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;uVYNOUUN3ME20Mlk4PTB7IN88US=>	NFu2VHpUSU6JRWK=
JVM-3	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHUTWM2OD13LkK1NFE1KM7:TR?=	M1HLd3NCVkeHUh?=
LAN-6	NGfXUXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjKTWM2OD13LkWxO\|M3KM7:TR?=	MlraV2FPT0WU
DJM-1	NH3iW4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;VT3dKSzVyPUWuOVYxOjlizszN	MnnOV2FPT0WU
JVM-2	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXmd4o1UUN3ME21MlY4ODl{IN88US=>	M3rrcHNCVkeHUh?=
U-87-MG	NH7JOVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTTTWM2OD13Lki5PVY1KM7:TR?=	NVnVd45HW0GQR1XS
SHP-77	MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DTV2lEPTB;NT65OFkzQCEQvF2=	Moi3V2FPT0WU
RPMI-8866	Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTZwMkewNVMh\|ryP	M12xe3NCVkeHUh?=
ES7	NGrXOW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXlTWM2OD14LkO5PVI1KM7:TR?=	M{Pxb3NCVkeHUh?=
WSU-NHL	NF;WXZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;SXWlEPTB;Nj61NVYxQSEQvF2=	MWTTRW5ITVJ?
CAS-1	NVLiTVVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGThWGxKSzVyPUeuNFk4PDlizszN	MkLmV2FPT0WU
MHH-NB-11	NGq3fW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRThwMkOxOVIh\|ryP	MmHEV2FPT0WU
ES5	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHNTWM2OD17LkWyNlg3KM7:TR?=	M2rhZ3NCVkeHUh?=
HDLM-2	MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3j4fmlEPTB;OT65OVkxOiEQvF2=	MkfJV2FPT0WU
NCI-H2171	NYnDXGRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHKNXZpUUN3ME2xNE42QTJ5IN88US=>	NWXRcI9KW0GQR1XS
LNCaP-Clone-FGC	NVn5PVI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLtTWM2OD1zMT6zO\|E5KM7:TR?=	MofnV2FPT0WU
NCI-H1395	NUfQUnNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfhTWM2OD1zMj6yOlk6KM7:TR?=	MlTMV2FPT0WU
NCI-H1436	NHH1W5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfrWo5KSzVyPUGzMlMyQTVizszN	MXvTRW5ITVJ?
RCC10RGB	M3yyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTF\|LkOyNlEh\|ryP	MnPpV2FPT0WU
SW684	NWPX[I95T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWj1TnlVUUN3ME2xN{46Pzl5IN88US=>	MWDTRW5ITVJ?
NCI-H1650	NF7NXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLvbVBKSzVyPUG1MlA1PDdizszN	M{f3enNCVkeHUh?=
EW-13	M{[zdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVy0PFdZUUN3ME2xOU4zODJzIN88US=>	MoPmV2FPT0WU
EC-GI-10	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1P1U2lEPTB;MUWuPFY1PCEQvF2=	Mn7xV2FPT0WU
CHP-126	NYfZXnJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DMWmlEPTB;MUeuNVkyQCEQvF2=	M3XTOXNCVkeHUh?=
NCI-H226	NELOOJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPITWM2OD1zOD6wOFA{KM7:TR?=	MoXiV2FPT0WU
NCI-H1838	MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33FfmlEPTB;MkCuNVg1QCEQvF2=	M3nHXnNCVkeHUh?=
EW-11	NXHvNFlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2roS2lEPTB;MkSuNlcyQCEQvF2=	M{PSS3NCVkeHUh?=
EB2	M2HNTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPtbHVKSzVyPUOxMlU{OThizszN	NE[0SXRUSU6JRWK=
D-502MG	MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIT0WZVKSzVyPUSzMlkzOjlizszN	NHfuWIVUSU6JRWK=
U-698-M	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfPe4lxUUN3ME20PE45PjdzIN88US=>	M3v4c3NCVkeHUh?=
ES3	NEPYUoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LoN2lEPTB;NEmuN\|g6OyEQvF2=	NGG3e3hUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	ATF4 / p-S6K(T389) / S6K / p-eIF2α(S51) / eIF2α / 4EBP1 / eIF3b; PubMed: 28494858 Cell Rep 4E-BPs are required for mTOR control of ATF4. 4E-BP1/2 wild-type (WT), double knockout (DKO), or DKO MEFs stably expressing 4ebp1 (DKO + 4ebp1) were treated with vehicle (DMSO) or 250 nM Torin 1 for 4 hr. Cell extracts were analyzed by immunoblotting for the indicated proteins. LC3 / p62 / PARP / pAKT(S473) / p4EBP1(S65) / pS6K1(T389) / pS6(S235/236); PubMed: 24126619 Int J Oncol Cells were treated with increasing doses of the mTOR inhibitors, torin 1 (A) and rapamycin (B), in RPMI-1640 containing 10% FBS for 2 days. LC3 processing, p62 accumulation, PARP cleavage, AKT phosphorylation and mTOR pathway activity (indicated by phosphorylation of 4E-BP, S6K1 and S6) were analyzed by western blotting of total cell lysates. GAPDH was the control for protein loading. p-mTOR(S2481) / mTOR / rictor / Sin1 / p-Akt S473 / p-Akt T450 / p-Akt T308 / p-S6K1 T389 / S6K1; PubMed: 21965657 J Biol Chem mTOR kinase activity controls abundance of SIN1. MDA-MB-435 cells were incubated with specific mTOR inhibitor (0.5 μm TORIN) for 24 or 48 h and analyzed. Vinculin / p-S6; PubMed: 28757207 Mol Cell A375 cells were treated with Torin1 for 48 h and localization of proteins was visualized by confocal microscopy. Scale bar, 50 μm. Focal adhesion size was measured by Fiji program.	28494858 24126619 21965657 28757207
Immunofluorescence	lipin-1; PubMed: 28347999 FASEB J Inhibition of mTOR activity promoted the nuclear translocation of lipin-1. After treatment with or without torin 1 for 4 h, cells expressing HA-lipin-1 were fixed and stained with a rabbit HA antibody followed by Alexa 594–conjugated goat anti-rabbit secondary antibody. Nuclei were stained with DAPI. Scale bars, 20 μM.	28347999
Growth inhibition assay	Cell viability; PubMed: 28757207 Mol Cell Cancer cell lines were grown in complete media with/without mTOR inhibitor, Torin1 (250 nM). Media and Torin1 were replaced every 2 days and cells were counted at the indicated time points. Data are the means ± SD of three separate experiments performed in triplicate.	28757207

In vivo

Torin1 is efficacious at a dose of 20 mg/kg in a U87MG xenograft model and demonstrates good pharmacodynamic inhibition of downstream effectors of mTOR in tumor and peripheral tissues. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse mTORC1 and mTORC2 in Vitro Kinase Assays: To produce soluble mTORC1, HEK-293T cell lines that stably express N-terminally FLAG-tagged Raptor are generated using vesicular stomatitis virus G-pseudotyped MSCV retrovirus. For mTORC2, similar HeLa cells that stably express N-terminally FLAG-tagged Protor-1 are generated. Both complexes are purified by lysing cells in 50 mm HEPES, pH 7.4, 10 mm sodium pyrophosphate, 10 mm sodium β-glycerophosphate, 100 mm NaCl, 2 mm EDTA, 0.3% CHAPS. Cells are lysed at 4 °C for 30 min, and the insoluble fraction is removed by microcentrifugation at 13,000 rpm for 10 min. Supernatants are incubated with FLAG-M2 monoclonal antibody-agarose for 1 h and then washed three times with lysis buffer and once with lysis buffer containing a final concentration of 0.5 M NaCl. Purified mTORC1 is eluted with 100 μg/mL 3×FLAG peptide in 50 mm HEPES, pH 7.4, 100 mm NaCl. Eluate can be aliquoted and stored at -80 °C. Substrates S6K1 and Akt1 are purified. Kinase assays are performed for 20 min at 30 °C in a final volume of 20 μL consisting of the kinase buffer (25 mm HEPES, pH 7.4, 50 mm KCl, 10 mm MgCl₂, 500 μm ATP) and 150 ng of inactive S6K1 or Akt1 as substrates. Reactions are stopped by the addition of 80 μL of sample buffer and boiled for 5 min. Samples are subsequently analyzed by SDS-PAGE and immunoblotting.
Cell Research:^[1]	- Collapse Cell lines: MEFs Concentrations: ~250 nM Incubation Time: 4 days Method: Cell viability is assessed with the CellTiter-Glo Luminescent Cell Viability Assay. On Day 0, 96-well plates are seeded with 500 cells per well and grown overnight. On Day 1, cells are treated with the appropriate compounds and subsequently analyzed on Days 3-5. For analysis, plates are incubated for 60 min at room temperature; 50 μL of CellTiter-Glo reagent is added to each well, and plates are mixed on an orbital shaker for 12 min. Luminescence is quantified on a standard plate luminometer. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: U87MG xenograft model Dosages: 20 mg/kg Administration: Administered via i.p. once daily (Only for Reference)

References

[4] Dowling RJ, et al, Science, 2010, 328(5982), 1172-1176.

- Collapse

Solubility (25°C)

In vitro	DMSO	2 mg/mL (3.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 20% NMP+50% PEG 400 For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Torin 1 SDF

Molecular Weight	607.62
Formula	C₃₅H₂₈F₃N₅O₂
CAS No.	1222998-36-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CCC(=O)N1CCN(CC1)C2=C(C=C(C=C2)N3C(=O)C=CC4=CN=C5C=CC(=CC5=C43)C6=CC7=CC=CC=C7N=C6)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to re-constitute the inhibitor for i.p. administration?
Answer:
S2827 Torin 1 can be dissolved in 5% DMSO/30% PEG 300/ddH2O at 0.25 mg/ml clearly, and in 10% DMSO/corn oil at 0.5 mg/ml, it is also a clear solution.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Selective mTOR inhibitor

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
Most Potent mTOR Inhibitor

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Dorsomorphin selectively inhibits the BMP type I receptors ALK2, ALK3 and ALK6. Dorsomorphin is used in promoting specific cell differentiation and inducing cancer cell line autophagy.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus, AY 22989, NSC-2260804) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay. Everolimus induces cell apoptosis and autophagy and inhibits tumor cells proliferation.
AZD8055

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. AZD8055 induces caspase-dependent apoptosis and also induces autophagy. Phase 1.

Features:First drug to inhibit both types of mTOR protein.
Temsirolimus (CCI-779)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay. Temsirolimus induces autophagy and apoptosis.
Sapanisertib (MLN0128)

Sapanisertib (MLN0128, INK 128, TAK-228) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506, FR900506, Fujimycin, Prograf) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex. Tacrolimus also inhibits the phosphatase activity of calcineurin. Tacrolimus induces vascular endothelial autophagy.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

Torin 1